RxDoctor Payments Data

Nnamdi Uhegwu, MD

Neurology · Sioux Falls, SDNPI 1861809717

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 36.4% of the total.

$923in general payments, 2019–2025

Across 38 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$336
  • AstraZeneca$154
  • Eisai Inc.$86
  • CSL Behring$79
  • Amgen$44
  • Amneal Pharmaceuticals LLC$29
  • plus $194 from 11 others

What the payments were for

  • Food & beverage$91099%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 55th percentile of 49 neurology providers in South Dakota.

See all neurology providers in South Dakota

Medicare billing

Part B allowed, 2024
$64,638
Medicare patients
398
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$89,738
Nurtec OdtRimegepant Sulfate28$37,827
BriviactBrivaracetam24$32,028
Aimovig AutoinjectorErenumab-Aooe31$24,476
UbrelvyUbrogepant11$13,867
Emgality SyringeGalcanezumab-Gnlm19$12,994
Emgality PenGalcanezumab-Gnlm12$9,767
Pyridostigmine Bromide ErPyridostigmine Bromide18$8,746
Lacosamide62$8,675
Ajovy AutoinjectorFremanezumab-Vfrm12$8,654
Gabapentin273$6,098
Pregabalin194$5,677
Levetiracetam175$5,038
Pyridostigmine Bromide24$4,220
Memantine Hcl157$2,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$13$32,02824 claims
AbbVieUbrelvy$336$13,86711 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$29$6,69556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 49 neurology providers in South Dakota.

Other neurology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →